The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases
- PMID: 32819825
- PMCID: PMC7855689
- DOI: 10.1016/j.jagp.2020.07.011
The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases
Abstract
Neuropsychiatric syndromes and symptoms play increasingly important roles in research diagnostic criteria for neurodegenerative disorders. Diagnostic criteria were reviewed including those for dementia, Alzheimer's disease, mild cognitive impairment, mild behavioral impairment, prodromal Alzheimer's disease, dementia with Lewy bodies, prodromal dementia with Lewy bodies, Parkinson's disease, multiple system atrophy, frontotemporal dementia, primary progressive aphasia, progressive supranuclear palsy, corticobasal degeneration, traumatic encephalopathy syndrome, Huntington' disease, amyotrophic lateral sclerorsis. All contemporary research diagnostic criteria for neurodegenerative disorders expect those for Parkinson's disease, primary progressive aphasia, multisystem atrophy and amyotrophic lateral sclerosis include neuropsychiatric phenomena as core diagnostic criteria. There are no disease-specific neuropsychiatric symptoms; apathy and disinhibition are common in tauopathies, and rapid-eye-movement sleep behavioral disorder occurs almost exclusively in synucleinopathies. Neuropsychiatric symptoms and syndromes are increasingly integrated into research diagnostic criteria for neurodegenerative disorders; they require clinician skills for recognition; their biology is better understood as their relationships to cognitive, motor, and autonomic symptoms of neurodegenerative disorders are studied.
Keywords: Alzheimer's disease; Neurodegenerative disorders; agitation; apathy; frontotemporal dementia, dementia with Lewy bodies, traumatic encephalopathy syndrome; neuropsychiatric syndromes.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflicts of Interest and Source of Funding
JC has provided consultation to Acadia, Actinogen, Alkahest, Allergan, Alzheon, Annovis, Avanir, Axsome, BiOasis, Biogen, Cassava, Cerecin, Cerevel, Cortexyme, Cytox, EIP Pharma, Eisai, Foresight, GemVax, Genentech, Green Valley, Grifols, Merck, Novo Nordisk, Otsuka, Resverlogix, Roche, Samumed, Samus, Signant Health, Third Rock and United Neuroscience pharmaceutical and assessment companies. JC owns the copyright of the Neuropsychiatric Inventory. JC is supported by KMA; NIGMS grant P20GM109025; NINDS grant U01NS093334; and NIA grant R01AG053798.
References
-
- Robert P, Onyike CU, Leentjens AF, et al.: Proposed diagnostic criteria for apathy in Alzheimer’s disease and other neuropsychiatric disorders. Eur Psychiatry 2009; 24:98–104 - PubMed
-
- Robert P, Lanctot KL, Aguera-Ortiz L, et al.: Is it time to revise the diagnostic criteria for apathy in brain disorders? The 2018 international consensus group. Eur Psychiatry 2018; 54:71–76 - PubMed
-
- American Psychiatric Association: Diagnostic and statistical manual, 5th ed., Washington, D.C., American Psychiatric Association Publishing, 2013
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical